ANCA相关血管炎诱导缓解后蛋白尿和血尿与结局相关
该事后分析纳入五项欧洲随机临床试验的571例ANCA相关血管炎患者,评估诱导治疗结束时尿蛋白肌酐比值(UPCR)和血尿与死亡/肾衰竭或复发的关系。中位随访28个月,UPCR≥0.05 g/mmol与死亡/肾衰竭及肾脏复发风险显著相关,持续血尿为肾脏复发的独立预测因子。
要点
- 诱导治疗后UPCR≥0.05 g/mmol与死亡/肾衰竭风险显著相关(调整HR 3.06)。
- 诱导治疗后UPCR≥0.05 g/mmol与肾脏复发风险显著相关(调整亚分布HR 2.22)。
- 持续血尿与肾脏复发显著相关(调整亚分布HR 2.16),但与任何器官复发及死亡/肾衰竭无关。
核心结论
- 在ANCA相关血管炎患者中,诱导治疗后持续蛋白尿与死亡/肾衰竭和肾脏复发相关,而持续血尿是肾脏复发的独立预测因子。
研究设计与样本
- 对五项欧洲随机临床试验(MAINRITSAN、MAINRITSAN2、RITUXVAS、MYCYC、IMPROVE)的事后分析,纳入571例患者。
主要发现
- 571例患者中59%为男性,中位年龄60岁,60%为抗蛋白酶3-ANCA,35%为抗髓过氧化物酶-ANCA,77%有肾脏受累。
- 诱导治疗后157/526(29.8%)有持续血尿,165/481(34.3%)UPCR≥0.05 g/mmol。
- 中位随访28个月(四分位距18-42),调整年龄、ANCA类型、维持治疗、血清肌酐和持续血尿后,UPCR≥0.05 g/mmol与死亡/肾衰竭显著相关(调整HR 3.06,95%CI 1.09-8.59),与肾脏复发显著相关(调整亚分布HR 2.22,95%CI 1.16-4.24)。
- 持续血尿与肾脏复发显著相关(调整亚分布HR 2.16,95%CI 1.13-4.11),但与任何器官复发及死亡/肾衰竭无关。
关键数值与推荐
- UPCR阈值0.05 g/mmol,诱导治疗结束时(治疗开始后4-6个月)留取点尿样本检测。
临床怎么用
- 作者认为,应考虑这些参数以评估ANCA相关血管炎患者的长期肾脏预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), hematuria and proteinuria are biomarkers reflecting kidney involvement at diagnosis. Yet, the prognostic value of their persistence after immunosuppressive induction therapy, reflecting kidney damage or persistent disease, remains uncertain. To study this, our post hoc analysis included participants of five European randomized clinical trials on AAV (MAINRITSAN, MAINRITSAN2, RITUXVAS, MYCYC, IMPROVE). Urine protein-creatinine ratio (UPCR) and hematuria of spot urine samples collected at the end of induction therapy (four-six months after treatment initiation) were correlated with the occurrence of a combined end point of death and/or kidney failure, or relapses during follow-up. Among 571 patients (59% men, median age 60), 60% had anti-proteinase 3-ANCA and 35% had anti-myeloperoxidase-ANCA, while 77% had kidney involvement. After induction therapy, 157/526 (29.8%) had persistent hematuria and 165/481 (34.3%) had UPCR of 0.05 g/mmol or more. After a median follow-up of 28 months (interquartile range 18-42), and adjustment for age, ANCA type, maintenance therapy, serum creatinine and persistent hematuria after induction, a UPCR of 0.05 g/mmol or more after induction was associated with significant risk of death/kidney failure (adjusted Hazard Ratio [HR] 3.06, 95% confidence interval 1.09-8.59) and kidney relapse (adjusted subdistribution HR 2.22, 1.16-4.24). Persistent hematuria was associated with significant kidney relapse (adjusted subdistribution HR 2.16, 1.13-4.11) but not with relapse affecting any organ nor with death/kidney failure. Thus, in this large cohort of patients with AAV, persistent proteinuria after induction therapy was associated with death/kidney failure and kidney relapse, whereas persistent hematuria was an independent predictor of kidney relapse. Hence, these parameters must be considered to assess long-term kidney prognosis of patients with AAV.
引用
- Benichou N, Charles P, Terrier B, et al. Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis. Kidney Int. 2023. PMID: 36940799. doi:10.1016/j.kint.2023.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。